Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Open-label, Dose Escalation and Safety Study of Human Spinal Cord derived Neural Stem Cell Transplantation for the treatment of Amyotrophic Lateral Sclerosis

Next Previous
X
Search
Trial Profile

A Phase II, Open-label, Dose Escalation and Safety Study of Human Spinal Cord derived Neural Stem Cell Transplantation for the treatment of Amyotrophic Lateral Sclerosis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jan 2020

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NSI 566 (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Adverse reactions
  • Sponsors Neuralstem; Seneca Biopharma

    • Most Recent Events

    • 03 May 2018 According to a Neuralstem media release, results of post-hoc comparison of combined cohorts from Phase 1 and 2 trials vs. historical controls were published in the Annals of Clinical and Translational Neurology.
    • 27 Jan 2016 According to a Neuralstem media release, data from this study was presented at the Phacilitate Cell & Gene Therapy World Conference, Washington D.C.
    • 29 Sep 2015 Results presented for 9 month phase II and combined phase I and phase II data presented at the American Neurological Association Annual Meeting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top